Dr. Poeschel on 6 Versus 4 Cycles of R-CHOP in Frontline DLBCL
Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.
Viola Poeschel, MD, department of hematology, oncology and rheumatology, Saarland University Medical School, Germany, discusses outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who were treated with 4 cycles of R-CHOP during the 2018 ASH Annual Meeting.
At a median follow-up of 66 months, the 3-year progression-free survival (PFS) rate was 94% for patients who received 6 cycles of frontline R-CHOP compared with 96% in those who received 4 cycles of frontline R-CHOP followed by 2 cycles of rituximab. The 3-year overall survival rates at a median follow-up of 67 months were 98% versus 99%, respectively.
